Want to see SE:SIMRIS.B full AI Analyst Report?
Top Page
Simris Alg AB Class B
(SIMRIS.B)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr0.11
▲(167.50% Upside)
Action:Reiterated
Date:09/15/26
The score is held down primarily by very weak financial performance: contracting revenue, negative gross profit and margins, persistent cash burn, and a highly leveraged/near-zero equity balance sheet that raises funding risk. Technicals provide some offset with the price trading above major moving averages, but momentum is mixed (slightly negative MACD). Valuation remains constrained by ongoing losses and the absence of a dividend yield.
Positive Factors
Microalgae Platform
A focused microalgae platform gives Simris exposure to biotechnology and nutrition applications, with potential relevance across dietary supplements and ingredient markets. This product foundation can support multiple commercial uses as the company develops and commercializes algae-derived offerings.
Negative Factors
Revenue and Gross Profit Decline
Contracting revenue combined with negative gross profit shows that the business is not currently generating enough sales or pricing power to cover direct costs. Persistent weakness at this level threatens scalability, limits reinvestment capacity, and leaves no clear near-term path to profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Microalgae Platform
A focused microalgae platform gives Simris exposure to biotechnology and nutrition applications, with potential relevance across dietary supplements and ingredient markets. This product foundation can support multiple commercial uses as the company develops and commercializes algae-derived offerings.
Read all positive factors
Simris Alg AB Class B (SIMRIS.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr139.70M
Dividend YieldN/A
Average Volume (3M)155.38K
Price to Earnings (P/E)―
Beta (1Y)0.11
Revenue Growth-46.23%
EPS Growth56.59%
CountrySE
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding1,349,793,200
10 Day Avg. Volume309,063
30 Day Avg. Volume155,381
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-76.69
Price to Sales (P/S)22.32
P/FCF Ratio-2.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Simris Alg AB Class B Business Overview & Revenue Model
Company Description
Operating both within Sweden and across global markets, Simris Alg AB (publ) specializes in the production and sale of nutritional supplements and food products derived from algae. Its product portfolio includes Simris Algae Omega-3, a unique plan...
How the Company Makes Money
Simris Alg AB makes money primarily by commercializing products and ingredients derived from microalgae. Its revenue model is typically based on (1) selling finished consumer products (e.g., algae-based nutritional oils or supplements) through dir...
Simris Alg AB Class B Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.39M | 1.61M | 2.89M | 4.35M | 4.08M | 6.14M |
| Gross Profit | -21.63M | -31.34M | 1.22M | 2.01M | -742.00K | -2.07M |
| EBITDA | -15.43M | -17.32M | -17.59M | -22.36M | -18.00M | -24.81M |
| Net Income | -25.63M | -26.81M | -34.60M | -37.30M | -24.42M | -28.36M |
Balance Sheet | ||||||
| Total Assets | 137.73M | 148.38M | 157.06M | 174.55M | 185.71M | 29.20M |
| Cash, Cash Equivalents and Short-Term Investments | 7.99M | 1.47M | 1.95M | 5.67M | 3.99M | 961.00K |
| Total Debt | 89.69M | 87.68M | 2.04M | 2.67M | 2.13M | 3.13M |
| Total Liabilities | 136.97M | 148.85M | 151.42M | 148.94M | 162.68M | 10.98M |
| Stockholders Equity | 767.00K | -470.00K | 5.64M | 25.61M | 23.03M | 18.22M |
Cash Flow | ||||||
| Free Cash Flow | -12.83M | -16.27M | -18.63M | -37.96M | -40.57M | -18.39M |
| Operating Cash Flow | -15.38M | -16.05M | -18.02M | -36.35M | -18.19M | -18.14M |
| Investing Cash Flow | -552.00K | -224.00K | -613.00K | -1.61M | -22.38M | -253.00K |
| Financing Cash Flow | 22.89M | 15.79M | 14.91M | 39.63M | 43.60M | 2.84M |
Simris Alg AB Class B Technical Analysis
Positive
0.04
Price Trends
0.11
Positive
0.10
Positive
0.09
Positive
Market Momentum
<0.01
Negative
58.21
Neutral
73.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SIMRIS.B, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.09, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.21 is Neutral, neither overbought nor oversold. The STOCH value of 73.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SIMRIS.B.
Simris Alg AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | kr959.17M | -11.08 | -89.70% | ― | ― | 19.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr139.70M | -4.05 | 1209.72% | ― | -46.23% | 56.59% | |
44 Neutral | kr13.19M | -0.09 | -46.30% | 1.17% | 1.80% | -1367.42% | |
41 Neutral | kr44.38M | -0.10 | -420.21% | ― | ― | 24.27% | |
41 Neutral | kr113.29M | -5.37 | -116.56% | ― | -37.50% | 0.99% |
* Healthcare Sector Average
SE:SIMRIS.B
Simris Alg AB Class B
0.12
-0.02
-15.44%
SE:IBT.B
Infant Bacterial Therapeutics AB
67.50
-2.50
-3.57%
SE:MAGLE
Magle Chemoswed Holding AB
0.70
-18.30
-96.32%
SE:BIOSGN
Biosergen AB
0.55
-4.95
-90.09%
SE:BIOEX
Bioextrax AB
2.33
-0.51
-17.84%
SE:BIOWKS
Bio-Works Technologies AB
3.32
0.70
26.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.